In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers. Industry partners are enabling data generation at ...

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...

EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...